WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced its strategy to secure 7.5 years of U.S. exclusivity ...

Approximately one in four patients died, deteriorated to a higher shock stage, or were transferred for a higher level of care ...

Cardiogenic shock happens when the heart suddenly can’t pump enough blood to meet the body’s needs. This leads to a drop in ...

If istaroxime is granted the new chemical entity designation from FDA, it could provide 7.5 years of U.S. exclusivity and additionally the istaroxime U.S. issued method of use patent protects until ...

Despite substantial advancements in the management of cardiogenic shock, mortality rates remain greater than 40%. Trials have ...